Colorectal Cancer Clinical Trial
— BiomHostOfficial title:
Digestive Biobank for Exploring Microbiota-host Interactions
Constitution of a biobank of tissues, whole blood and plasma samples and stools to identify markers associated with treatment response, postoperative morbidity including neuro-cognitive and mood complications and prognosis of Inflammatory Bowel disease or colorectal cancer.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | September 17, 2026 |
Est. primary completion date | September 17, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Ulcerative colitis, Crohn's disease or colorectal disease - Digestive resection with useless tissue available - Information consent signed Exclusion Criteria: - Patients < 18 years |
Country | Name | City | State |
---|---|---|---|
France | Service de Chirurgie Viscérale - Hôpital Saint Antoine | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Relation between biological parameters and outcomes of digestive disease (IBD, CRC) | identify relations between serumon response to treatment, postoperative outcomes including neuro-cognitive and mood complications and prognosis. | up to 12 months after the incusion | |
Secondary | Relation between biological parameters and outcomes of digestive disease (IBD, CRC) | identify relations between plasma on response to treatment, postoperative outcomes including neuro-cognitive and mood complications and prognosis. | up to 12 months after the incusion | |
Secondary | Relation between biological parameters and outcomes of digestive disease (IBD, CRC) | identify relations between DNA on response to treatment, postoperative outcomes including neuro-cognitive and mood complications and prognosis. | up to 12 months after the incusion | |
Secondary | Relation between biological parameters and outcomes of digestive disease (IBD, CRC) | identify relations between faeces) on response to treatment, postoperative outcomes including neuro-cognitive and mood complications and prognosis. | up to 12 months after the incusion | |
Secondary | Exploratory study on the physiopathology of host-microbiota interactions to determinate the occurrence of intestinal and extra-intestinal complications | genetic polymorphisms, serum markers, intestinal microbiota markers to determining the occurrence of intestinal and extra-intestinal complications | up to two months after the incusion | |
Secondary | Exploratory study on the physiopathology of host-microbiota interactions to determinate the response to treatments | genetic polymorphisms, serum markers, intestinal microbiota markers determining : response to treatments | up to two months after the incusion | |
Secondary | Exploratory study on the physiopathology of host-microbiota interactions | genetic polymorphisms, serum markers, intestinal microbiota markers determining : interactions between host and microbiota | up to two months after the incusion | |
Secondary | Brain-microbiota interaction | Exploring the pathophysiology of host-microbiota interactions in postoperative cognitive or behavioral changes involving inflammation pathways | up to two months after the incusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |